Literature DB >> 32150608

CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation.

Boris A Bartholdy1, Xiahoua Wang1, Xiao-Jie Yan2, Marién Pascual3,4,5, Manxia Fan1, Jacqueline Barrientos2,6, Steven L Allen2,6, Jose Angel Martinez-Climent3,4,5, Kanti R Rai2,6, Nicholas Chiorazzi2,6,7, Matthew D Scharff1, Sergio Roa3,4,5.   

Abstract

Intraclonal subpopulations of circulating chronic lymphocytic leukemia (CLL) cells with different proliferative histories and reciprocal surface expression of CXCR4 and CD5 have been observed in the peripheral blood of CLL patients and named proliferative (PF), intermediate (IF), and resting (RF) cellular fractions. Here, we found that these intraclonal circulating fractions share persistent DNA methylation signatures largely associated with the mutation status of the immunoglobulin heavy chain locus (IGHV) and their origins from distinct stages of differentiation of antigen-experienced B cells. Increased leukemic birth rate, however, showed a very limited impact on DNA methylation of circulating CLL fractions independent of IGHV mutation status. Additionally, DNA methylation heterogeneity increased as leukemic cells advanced from PF to RF in the peripheral blood. This frequently co-occurred with heterochromatin hypomethylation and hypermethylation of Polycomb-repressed regions in the PF, suggesting accumulation of longevity-associated epigenetic features in recently born cells. On the other hand, transcriptional differences between paired intraclonal fractions confirmed their proliferative experience and further supported a linear advancement from PF to RF in the peripheral blood. Several of these differentially expressed genes showed unique associations with clinical outcome not evident in the bulk clone, supporting the pathological and therapeutic relevance of studying intraclonal CLL fractions. We conclude that independent methylation and transcriptional landscapes reflect both preexisting cell-of-origin fingerprints and more recently acquired hallmarks associated with the life cycle of circulating CLL cells.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32150608      PMCID: PMC7065474          DOI: 10.1182/bloodadvances.2019000817

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  50 in total

1.  High density DNA methylation array with single CpG site resolution.

Authors:  Marina Bibikova; Bret Barnes; Chan Tsan; Vincent Ho; Brandy Klotzle; Jennie M Le; David Delano; Lu Zhang; Gary P Schroth; Kevin L Gunderson; Jian-Bing Fan; Richard Shen
Journal:  Genomics       Date:  2011-08-02       Impact factor: 5.736

2.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

3.  Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia.

Authors:  Marta Kulis; Simon Heath; Marina Bibikova; Ana C Queirós; Alba Navarro; Guillem Clot; Alejandra Martínez-Trillos; Giancarlo Castellano; Isabelle Brun-Heath; Magda Pinyol; Sergio Barberán-Soler; Panagiotis Papasaikas; Pedro Jares; Sílvia Beà; Daniel Rico; Simone Ecker; Miriam Rubio; Romina Royo; Vincent Ho; Brandy Klotzle; Lluis Hernández; Laura Conde; Mónica López-Guerra; Dolors Colomer; Neus Villamor; Marta Aymerich; María Rozman; Mónica Bayes; Marta Gut; Josep L Gelpí; Modesto Orozco; Jian-Bing Fan; Víctor Quesada; Xose S Puente; David G Pisano; Alfonso Valencia; Armando López-Guillermo; Ivo Gut; Carlos López-Otín; Elías Campo; José I Martín-Subero
Journal:  Nat Genet       Date:  2012-10-14       Impact factor: 38.330

4.  450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments.

Authors:  N Cahill; A-C Bergh; M Kanduri; H Göransson-Kultima; L Mansouri; A Isaksson; F Ryan; K E Smedby; G Juliusson; C Sundström; A Rosén; R Rosenquist
Journal:  Leukemia       Date:  2012-08-27       Impact factor: 11.528

5.  DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation.

Authors:  Anne Y Lai; Deepak Mav; Ruchir Shah; Sara A Grimm; Dhiral Phadke; Katerina Hatzi; Ari Melnick; Cissy Geigerman; Steve E Sobol; David L Jaye; Paul A Wade
Journal:  Genome Res       Date:  2013-09-06       Impact factor: 9.043

6.  Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.

Authors:  E J Murphy; D S Neuberg; L Z Rassenti; G Hayes; R Redd; C Emson; K Li; J R Brown; W G Wierda; S Turner; A W Greaves; C S Zent; J C Byrd; C McConnel; J Barrientos; N Kay; M K Hellerstein; N Chiorazzi; T J Kipps; K R Rai
Journal:  Leukemia       Date:  2017-01-24       Impact factor: 11.528

7.  Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.

Authors:  Thomas M Herndon; Shih-Shih Chen; Nakhle S Saba; Janet Valdez; Claire Emson; Michelle Gatmaitan; Xin Tian; Thomas E Hughes; Clare Sun; Diane C Arthur; Maryalice Stetler-Stevenson; Constance M Yuan; Carsten U Niemann; Gerald E Marti; Georg Aue; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Nicholas Chiorazzi; Adrian Wiestner
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

8.  Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia.

Authors:  Pedro G Ferreira; Pedro Jares; Daniel Rico; Gonzalo Gómez-López; Alejandra Martínez-Trillos; Neus Villamor; Simone Ecker; Abel González-Pérez; David G Knowles; Jean Monlong; Rory Johnson; Victor Quesada; Sarah Djebali; Panagiotis Papasaikas; Mónica López-Guerra; Dolors Colomer; Cristina Royo; Maite Cazorla; Magda Pinyol; Guillem Clot; Marta Aymerich; Maria Rozman; Marta Kulis; David Tamborero; Anaïs Gouin; Julie Blanc; Marta Gut; Ivo Gut; Xose S Puente; David G Pisano; José Ignacio Martin-Subero; Nuria López-Bigas; Armando López-Guillermo; Alfonso Valencia; Carlos López-Otín; Elías Campo; Roderic Guigó
Journal:  Genome Res       Date:  2013-11-21       Impact factor: 9.043

9.  DiffVar: a new method for detecting differential variability with application to methylation in cancer and aging.

Authors:  Belinda Phipson; Alicia Oshlack
Journal:  Genome Biol       Date:  2014-09-23       Impact factor: 13.583

10.  AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.

Authors:  Matt Teater; Pilar M Dominguez; David Redmond; Zhengming Chen; Daisuke Ennishi; David W Scott; Luisa Cimmino; Paola Ghione; Jayanta Chaudhuri; Randy D Gascoyne; Iannis Aifantis; Giorgio Inghirami; Olivier Elemento; Ari Melnick; Rita Shaknovich
Journal:  Nat Commun       Date:  2018-01-15       Impact factor: 14.919

View more
  1 in total

1.  FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.

Authors:  Vaclav Seda; Eva Vojackova; Laura Ondrisova; Lenka Kostalova; Sonali Sharma; Tomas Loja; Gabriela Mladonicka Pavlasova; Daniel Zicha; Marie Kudlickova Peskova; Jan Krivanek; Kvetoslava Liskova; Leos Kren; Vladimir Benes; Katerina Musilova Litzmanova; Marek Borsky; Jan Oppelt; Jan Verner; Sarka Pospisilova; Yvona Brychtova; Anna Panovska; Zhi Tan; Shuxing Zhang; Michael Doubek; Katerina Amruz Cerna; Jiri Mayer; Marek Mraz
Journal:  Blood       Date:  2021-09-02       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.